METHOD FOR CORRECTION OF TREATMENT OF PATIENTS WITH TUBERCULOSIS WITHOUT BACTERIOEXCRETION BY X-RAY EXAMINATION DATA Russian patent published in 2017 - IPC A61B6/03 A61B17/00 

FIELD: medicine.

SUBSTANCE: according to the X-ray computed tomography of chest organs (CO X-ray CT) the largest focus of tuberculous infiltrate - the main focus - is determined. Its mean radius Rmean is calculated: R_mean=(R₁+R₂+R₃)/3, where R₁, R₂, R₃ are the radii of the main focus as a spherical body in three-dimensional space along the x, y, z axes. Then the volume of the main focus is calculated by the formula: V=4/3×πR_mean³ the main focus volume change coefficient (M_FVCC) is calculated: (M_FVCC)=(V_{2_after treatment /} V_{1_before treatment})×100%, where V_{2_after treatment} is the volume of the main focus of infiltration on the roentgenogram after 2 months of treatment, V_{1_ before treatment} is the volume of the main focus of infiltration on the roentgenogram before treatment. If M_FVCC exceeds 80%, then the patient has negative dynamics of the tuberculosis process, high risk of multiple drug resistance (MDR) of tuberculosis mycobacteria (TMB), and surgical treatment is recommend. If M_FVCC is from 51 to 80%, then the patient has moderate positive dynamics, and chemotherapy is continued for a month with a subsequent evaluation of M_FVCC. According to its change of no more than 10% in a month, retained high risk of TMB MDR is judged, and surgical treatment is recommended. If MFVCC is 50% or less, the chemotherapy regimen is effective, TMB MDR risk is low and the patient is recommended to continue chemotherapy.

EFFECT: method provides individual quantitative prediction of hidden TMB MDR in patients of this group for the subsequent correction of treatment and, accordingly, a decrease in the number of disease relapses.

2 ex